# IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients

> **NCT05641545** · PHASE1 · TERMINATED · sponsor: **SLK Kliniken Heilbronn GmbH** · enrollment: 1 (actual)

## Conditions studied

- Advanced Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** IVAC

## Key facts

- **NCT ID:** NCT05641545
- **Lead sponsor:** SLK Kliniken Heilbronn GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-17
- **Primary completion:** 2024-09-15
- **Final completion:** 2024-09-15
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Premature discontinuation due to üoor participant recruitment
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05641545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05641545, "IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05641545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*